HENDERSON, Nev. --(BUSINESS WIRE)--May 29, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York .

Enrollment of cohort 2 was completed six months ahead of schedule Cohort 2 had a target enrollment of 87 NSCLC patients with HER2 exon 20 insertion mutations Topline results from cohort 2 are expected in mid 2020 Topline results from cohort 1, which enrolled NSCLC patients with EGFR exon 20

HENDERSON, Nev. --(BUSINESS WIRE)--May 16, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the 20th Annual B. Riley FBR Investor Conference being held in Beverly Hills, CA.

Topline results in the previously treated EGFR cohort (cohort 1) of the poziotinib ZENITH20 trial are expected in Q4 2019. Integrated data from the two Phase 3 ROLONTIS ® (eflapegrastim) clinical trials will be presented in a poster session at the American Society of Clinical Oncology 2019 annual

The Focused Interferon Therapeutics (FIT) platform is a proprietary targeted antibody-interferon fusion technology with potential broad application in oncology This asset purchase adds two innovative early-stage drug candidates to Spectrum’s existing pipeline and advances the oncology strategy

HENDERSON, Nev. --(BUSINESS WIRE)--May 2, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on

HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 2, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today that an overview of the company's business strategy and development-stage programs will be given at the H.C. Wainwright Global Life Sciences Conference being held in London .

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 15, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that due to the U.S. Food and Drug Administration’s ( FDA ) request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 13, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 1, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today completed the sale of its portfolio of seven FDA -approved hematology/oncology products to Acrotech Biopharma

Poziotinib enrollment completed in previously treated EGFR cohort (cohort 1) of ZENITH20 trial; topline results are expected in Q4 2019 ROLONTIS ® (eflapegrastim) Biologics License Application (BLA) was submitted to the FDA Q4 Revenues were $29.4 million , including $28.0 million in product sales;

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 21, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the fourth quarter and full year 2018 financial results, provide an update on the company's business, and discuss expectations for

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 7, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced today that an overview of the company's business strategy and development-stage programs will be given at the Guggenheim Healthcare Talks Idea Forum | Oncology Day being held in New York .

Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones Staff size will be reduced by approximately 40 percent with the majority of impacted staff transitioning to Acrotech Spectrum will retain a core group of commercial talent

Results are expected in the second half of 2019 HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 2, 2019-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today

Submission based on results from two large, positive pivotal trials Both pivotal trials successfully met their primary endpoint and all secondary endpoints ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) that utilizes a proprietary platform technology to maximize the

Spectrum will host a live webcast today at 4:30 p.m. EST / 1:30 p.m. PST HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 19, 2018-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), today announced that based on a subset of data from MD Anderson’s ongoing Phase 2 study, the U.S.

Primary endpoint of non-inferiority in the Duration of Severe Neutropenia (DSN) between ROLONTIS and pegfilgrastim was met No statistically significant differences in adverse event rates between treatment groups RECOVER is the second ROLONTIS Phase 3 study to meet the primary efficacy endpoint of

In practice, FOLOTYN use has caused Grade 2 or higher oral mucositis in more than half of patients, potentially impacting treatment of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) This was the first prospective study to evaluate the effect of oral leucovorin in preventing or reducing

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 30, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced presentations of clinical and scientific data